Comparing mRNA profiles from clinical specimens of ibrutinib‐resistant and sensitive MCL led to the identification of several resistance‐associated signatures, with a MYC‐driven transcriptional program being the most significantly enriched [101]. This evidence concerns the gene MYC and mantle cell lymphoma.